Stricter criteria will now apply to venue selection in ANDA patent disputes
In the way it has cleared up TC Heartland uncertainties relating to Hatch-Waxman litigation, the CAFC will have disappointed branded pharma companies
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.